Compare Charles River Laboratories Intl. Inc (CRL) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Mongodb Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Mongodb Inc trades at $347.22 (market cap $27.72B). The key difference: Mongodb Inc is far larger — about 2.5× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| CRL | MDB | |
|---|---|---|
Market Cap | $11.14B | $27.72B |
Sector | Health | Technology |
52-Week High | $233.60 | $440.25 |
52-Week Low | $145.57 | $201.08 |
Enterprise Value | $14.00B | $25.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
MongoDB (MDB) trades at $337.59, down 1.31% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. Revenue growth remains strong, reaching $2.01 billion in 2025, though the company is not yet profitable, posting a net loss of $129 million. Recent news highlights AI-driven demand boosting database sales, with the company raising FY2027 revenue guidance to $2.92–$2.96 billion, signaling robust growth prospects.
The outlook is positive given strong analyst support (81.8% buy ratings) and a $400.39 consensus price target, implying 18.6% upside. Key risks include ongoing losses, competitive pressures, and potential legal scrutiny from shareholder investigations. Earnings beats in recent quarters and projected narrowing losses by 2026 support a growth-oriented investment case, but profitability remains a critical watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
